Pfizer Inc. (NYSE:PFE) Shares Sold by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 13.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,866 shares of the biopharmaceutical company’s stock after selling 1,430 shares during the period. Redhawk Wealth Advisors Inc.’s holdings in Pfizer were worth $257,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer during the second quarter valued at approximately $31,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Thursday, October 3rd. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Trading Down 0.3 %

Pfizer stock opened at $29.08 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $33.92. The firm’s 50-day moving average is $29.02 and its 200-day moving average is $28.40. The company has a market cap of $164.78 billion, a P/E ratio of -484.67, a PEG ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.78%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.